Defying Market Headwinds, Zelun Bio Raises RMB 400 Million to Advance Global-Stage Innovative Drug Pipeline

　　【Pharmaceutical Network Enterprise News] Amid a cooling capital market in the global pharmaceutical industry and a significant slowdown in biopharmaceutical financing, the financing activities of innovative drug companies have drawn considerable attention. Recently, Zenitar, an innovative drug research and development company driven by structural biology and artificial intelligence, announced the completion of a nearly 400 million RMB B+ round of financing. This counter-trend financing achievement not only demonstrates the capital market's recognition of its development potential but also highlights its competitiveness in the biopharmaceutical field.
 

It is reported that Zenitar is an innovative drug research and development company driven by structural biology and artificial intelligence. Although a young biopharmaceutical technology company, it has already made a name for itself in the industry. Its independent R&D capabilities cover various aspects of innovative drug development, including target research and mechanism validation, drug molecular design, preclinical evaluation, CMC research, clinical trial design and execution, and new drug registration, creating a distinctive platform for innovative drug discovery.
 

Strong R&D capabilities are the key for Zenitar to win the favor of the capital market. In terms of technological innovation, the company continuously pushes boundaries, such as proposing the entirely new structure-based molecular generation framework CMD-GEN, which can efficiently design selective inhibitors, addressing many challenges faced by AI in drug molecule generation and bringing breakthrough progress to the field of AI-driven drug discovery. The team has also developed algorithms like the Local Skeleton Diversity-enhanced Molecular Generation Algorithm (LSDC), improving the efficiency and accuracy of molecular design and drug-likeness optimization. Meanwhile, for critical parameters in drug-likeness optimization, such as hERG prediction, the team has completed the development of multimodal pre-trained models, significantly enhancing the generalization ability and prediction accuracy of the models. Additionally, the formula-guided network model CMD-FGKpuu proposed by the team can efficiently predict a drug's ability to cross the blood-brain barrier, providing a powerful tool for the development of drugs targeting neurological disorders.
 

In the R&D pipeline, Zenitar focuses on major disease areas such as malignant tumors, inflammation, and autoimmune diseases. Through differentiated strategies, it has built a rich product portfolio. Currently, the company owns seven R&D pipelines for Class 1 new drugs. Among them, three varieties cover six indications in Phase II clinical trials, one in Phase I, one with an IND, and two in preclinical stages. The company has obtained 18 clinical trial approvals from the National Medical Products Administration of China and the U.S. FDA for Phase I and Phase II trials. Core products, Puyitini Mesylate and Flunotinib Maleate, have demonstrated promising clinical efficacy and possess the potential to become Best-in-Class and First-in-Class drugs. As a next-generation small-molecule kinase inhibitor, Flunotinib Maleate exhibits unique clinical advantages in treating myeloproliferative neoplasms by selectively inhibiting the JAK2, FLT3, and CDK6 signaling pathways. Preclinical studies indicate that it offers higher selectivity and lower toxicity compared to existing therapies.
 

The broad market prospects provide ample space for Zenitar's development. Taking the myelofibrosis drug market as an example, research institutions report that the current global market size for myelofibrosis drugs is approximately $4.5 billion, while the overall market for myeloproliferative neoplasms has reached nearly $10 billion. With further improvements in disease diagnosis and treatment rates, as well as the penetration rate of targeted drugs, the market's attention to new therapeutic solutions continues to rise, and Zenitar's products under development precisely meet this market demand.
 

The funds raised by Zenitar in this financing will be mainly used to advance multiple innovative drugs into pivotal Phase III clinical trials, support the continuous expansion of new R&D pipelines, and strengthen its three core technology platforms. It can be foreseen that, with the support of funding, Zenitar will accelerate its R&D progress. With its strong R&D capabilities, rich product pipeline, and broad market prospects, Zenitar is expected to achieve more accomplishments in the future biopharmaceutical field.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.